Schedule 13G ownership disclosure

Kura Oncology Inc

Common Stock, par value $0.0001 per share · CUSIP: 50127T109

Event date: 2024-12-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • SUVRETTA CAPITAL MANAGEMENT, LLC

    Shares: 5,198,189.00 · Class: 6.7%

  • Averill Master Fund, Ltd.

    Shares: 4,592,673.00 · Class: 5.9%

  • Aaron Cowen

    Shares: 5,198,189.00 · Class: 6.7%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000919574-25-001296
Form type
SCHEDULE 13G/A
Filer
Kura Oncology, Inc.
CIK
CIK 1422143
Filed
Feb 13, 2025
Reporting period
Dec 31, 2024
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub